POS-300 Patient-reported early stage chronic kidney disease

• A. ABDUL SULTAN,
• E. Wittbrodt,
• E. Malvolti,
• J. Guzek,
• L. Webber,
• L. Retat,
• J.J. Garcia Sanchez,
• C. Hungta,
• S. Barone

Affiliations

A. ABDUL SULTAN

AstraZeneca, Global Medical BioPharmaceutical- BioPharmaceuticals, Cambridge, United Kingdom

E. Wittbrodt

Astrazeneca, Global Medical BioPharmaceutical- BioPharmaceuticals, Gaithersburg, United States

E. Malvolti

AstraZeneca, Global Medical BioPharmaceutical- BioPharmaceuticals, Cambridge, United Kingdom

J. Guzek

HealthLumen Limited, Mathematical Modelling Department, London, United Kingdom

L. Webber

HealthLumen Limited, Mathematical Modelling Department, London, United Kingdom

L. Retat

HealthLumen Limited, Mathematical Modelling Department, London, United Kingdom

J.J. Garcia Sanchez

Astrazeneca, Global Market Access & Pricing BioPharmaceuticals, Cambridge, United Kingdom

C. Hungta

Astrazeneca, Biometerics- R&D BioPharmaceuticals, Gaithersburg, United States

S. Barone

Astrazeneca, Global Medical BioPharmaceutical- BioPharmaceuticals, Gaithersburg, United States